Zobrazeno 1 - 10
of 127
pro vyhledávání: '"S. Poongulali"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kawsar R Talaat, Subash Babu, Pradeep Menon, N Kumarasamy, Jabin Sharma, Jeeva Arumugam, Kalaivani Dhakshinamurthy, Ramalingam Srinivasan, S Poongulali, Wenjuan Gu, Michael P Fay, Soumya Swaminathan, Thomas B Nutman
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 9, Iss 3, p e0003622 (2015)
BACKGROUND:The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly acquired coincident infections. METHODOLOGY/PRINCIPAL FINDINGS:To assess the influence of pre-existing Wuchereria bancrofti infection on HIV pro
Externí odkaz:
https://doaj.org/article/93d12b3d396e4b6fb67cfa1d33d2ad97
Autor:
Ramachandran Vignesh, K G Murugavel, Jayshree Dhande, Manisha Ghate, S. Poongulali, Smita Kulkarni, Madhuri Thakar, Paneerselvam Nandagopal, Mansa Angadi
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 79:277-282
BACKGROUND Fragment crystallizable region of antibody-mediated mechanism such as antibody-dependent cellular cytotoxicity (ADCC) has been identified as an important component of immune protection against HIV. We assessed whether the anti-HIV antibodi
Autor:
Pachamuthu Balakrishnan, S. Poongulali, Rao B. Srirama, Shanmugam Saravanan, Jayaseelan Boobalan, Dhakshinamoorthy Subashini, Devaraj A. Chitra, Suniti Solomon, Sunil S. Solomon, S. N. Mothi, Thongadi Ramesh Dinesha
Publikováno v:
The Indian Journal of Medical Research
Indian Journal of Medical Research, Vol 148, Iss 2, Pp 207-214 (2018)
Indian Journal of Medical Research, Vol 148, Iss 2, Pp 207-214 (2018)
Background & objectives: Nucleoside reverse transcriptase inhibitors (NRTIs) are known to cause mitochondrial toxicity. This study was done to estimate mitochondrial DNA (mtDNA) content of peripheral blood mononuclear cells (PBMCs) among human immuno
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pradeep Ambrose, C Ezhilarasi, Nagalingeswaran Kumarasamy, S Poongulali, Jeffrey D. Jenks, C Devaraj, T Yepthomi, Constance A. Benson
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 20:1181-1184
SETTING Y R Gaitonde Centre for AIDS Research and Education, Chennai, India. OBJECTIVE To compare anti-tuberculosis treatment outcomes in individuals with human immunodeficiency virus (HIV) and tuberculosis (TB) co-infection on atazanavir/ritonavir (
Autor:
S. Poongulali, Thongadi Ramesh Dinesha, Ambrose Pradeep, Suniti Solomon, Dhakshinamoorthy Subashini, Shanmugam Saravanan, Sunil S. Solomon, Pachamuthu Balakrishnan, Lawrence Christopher Samuel, Jayaseelan Boobalan
Publikováno v:
Indian Journal of Pharmacology
Background: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor (PI) option for HIV patients in resource-limited settings; its pattern of adverse drug reactions (ADRs) has not been much reported from India; hence, in
Autor:
Sathasivam Sivamalar, Selvamurthi Gomathi, Shanmugam Saravanan, Pachamuthu Balakrishnan, Ambrose Pradeep, Jayaseelan Boobalan, Suniti Solomon, Thongadi Ramesh Dinesha, Sunil S. Solomon, S. Poongulali
Publikováno v:
AIDS Research and Human Retroviruses. 32:1234-1236
According to 2013 WHO guidelines, tenofovir (TDF) is the preferred first-line regimen for adults and adolescents. A total of 167 HIV-1-infected patients attaining immunological failure after TDF-based first-line HAART were included in this study, RT
Autor:
Robert W. Coombs, Susan Cu-Uvin, Susan H. Eshleman, Irving F. Hoffman, Jonathan Uy, Donna Mildvan, David W. Haas, Thomas B. Campbell, Kelly Burke, David D. Celentano, Edith Swann, Ronald T. Mitsuyasu, Ann C. Collier, Beatriz Grinsztejn, Newton Kumwenda, Laurie Frarey, Breno Santos, Apsara Nair, Ann Walawander, David Chilongozi, Bartolo Santos, Taha E. Taha, Chiedza Maponga, Sima Berendes, S. Poongulali, M. P. Revuelta, Charles van der Horst, Robert C. Bollinger, Suniti Solomon, Jorge Sanchez, Francis Martinson, N. Kumarasamy, Joan Dragavon, James Hakim, Rosa Infante, Richard B. Pendame, Farida Amod, Roy M. Gulick, Jody Lawrence, P. Jan Geiseler, Joan Gormley, Judith S. Currier, Cynthia Firnhaber, Laura Moran, Larisa Zifchak, Myron S. Cohen, Keith A. Pappa, Beverly Putnam, Charles Flexner, David H. Haas, Sandra W. Cardoso, Karin L. Klingman, Ruben Lopez, Joel E. Gallant, James F. Rooney, Jabin Sharma, Edde Loeliger, Pablo Tebas, Beverly E. Sha, Barbara Brizz, Wendy Snowden, Scott M. Hammer, Johnstone Kumwenda, Javier R. Lama, Karin Nielsen, Christine Wanke, Steve Tabet, Alberto La Rosa, Wadzanai Samaneka, Joseph J. Eron, Michael K. Klebert, Renard S. Descallar, Bharat Ramratnam, Kenneth H. Mayer, Cheryl Marcus, Yvonne J. Bryson, Nikki Gettinger, Vicki L. Bailey, Adriana Andrade, David Shugarts, Robert T. Schooley, Ken Braun, David Currin, Eric S. Daar, Michael Hughes, Laura M. Smeaton, Vladimir Berthaud, Sharlaa Badal-Faesen, Victor De Gruttola, Cecelia Kanyama, Timothy P. Flanigan, Mark A. Winters, Yvette Delph, Smanga Ntshele, Peter N. Kazembe, Deise Lucia Faria, Mina C. Hosseinipour, Steven A. Safren, Ronald L. Barnett, Ana Martinez, Abel Tilahun Eshete, Beth D. Mullan, Henry H. Balfour, Ge-Youl Kim, Anthony Chisada, Yajing Bao, Ian Sanne, Virginia Kayoyo, Susan A. Fiscus, Janice M. Fritsche, Nancy Webb
Publikováno v:
Clinical Infectious Diseases. 57:290-297
Background. Combination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but little is known about the efficacy of cART for decreasing genital tract vira
Autor:
S. Poongulali, Pachamuthu Balakrishnan, Sunil S. Solomon, Ambrose Pradeep, Selvamurthi Gomathi, Shanmugam Saravanan, Suniti Solomon, Jayaseelan Boobalan, Sathasivam Sivamalar, Thongadi Ramesh Dinesha
Publikováno v:
AIDS research and human retroviruses. 33(3)
Lack of HIV-1 viral load monitoring in resource-limited settings leads to the development of HIV drug resistance mutations, although WHO recommends viral load testing for monitoring as this helps in preserving future treatment options and also avoid